Nucleic Acid Preparations Identify Norovirus and Mycoplasma pneumonia
By LabMedica International staff writers Posted on 15 Oct 2013 |

Image: DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of Norovirus and Mycoplasma pneumonia.
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Latest Technology News
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more